Abbott’s Absorb GT1 Bioresorbable Scaffold Gets FDA Panel Date
This article was originally published in The Gray Sheet
Abbott Laboratories' Absorb GT1 Bioresorbable Vascular Scaffold System will soon be the first fully bioresorbable coronary scaffold to undergo FDA panel review. During a two-day Circulatory Systems Devices panel meeting in March, the panel will assess Absorb as well as Angel Medical System’s Angelmed Guardian System, an implantable monitor made to alert patients to coronary ischemia.
Register for our free email digests: